SUBLICENSE RIGHTS AGREEMENTPatent Sublicense Agreement • March 17th, 2023 • Delaware
, 2023 (the “Effective Date”) by and between Allied Security Trust I, a Delaware statutory trust with an address at 100 Overlook Center, 2nd Floor, Princeton, NJ 08540 (“AST”),
Patent Sublicense AgreementPatent Sublicense Agreement • March 16th, 2022 • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • June 28th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments • California
This Patent License Agreement (the “Agreement”), dated December 27, 2013 (the “Effective Date”), is hereby entered into by and between Industry 3200, Inc., a Delaware Corporation with a principal office located at 1155 Camino Del Mar #118, Del Mar, CA 92014 (“Sublicensor”), and BioNano Genomics, Inc., a Delaware Corporation, having a principal place of business at 9640 Towne Centre Drive, Suite 100 (“Sublicensee)
PATENT SUBLICENSE AGREEMENT,Patent Sublicense Agreement • June 22nd, 2006 • Lemaitre Vascular Inc • Surgical & medical instruments & apparatus • Arizona
This Agreement, by and between IMPRA, Inc., an Arizona corporation (hereinafter called LICENSOR), and Endomed, Inc., also an Arizona corporation (hereinafter called LICENSEE), effective as of Match 7, 2003,
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Patent Sublicense AgreementPatent Sublicense Agreement • September 9th, 2019 • BioNTech SE • Biological products, (no disgnostic substances) • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between mRNA RiboTherapeutics, Inc., a Wisconsin corporation having a place of business at 726 Post Road, Madison, WI 53713, USA (“mRNA RiboTherapeutics”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date“). Each of Company and mRNA RiboTherapeutics are referred to herein as a “Party” and collectively as the “Parties”.
Patent Sublicense AgreementPatent Sublicense Agreement • October 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • May 8th, 2019 • Manhattan Scientifics Inc • Miscellaneous electrical machinery, equipment & supplies • New Mexico
This Patent Sublicense Agreement (this “Sublicense Agreement”) dated as of May 1, 2019 (the “Effective Date”) is made and entered into by and between MANHATTAN SCIENTIFICS, INC., a Delaware corporation having its principal place of business at The Chrysler Building, 26th Floor, 405 Lexington Avenue, New York, New York 10174 (“MSI”) and [**] with offices located at [**] (“LICENSEE”).
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • December 22nd, 2006 • Ceragenix Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This PATENT SUBLICENSE AGREEMENT (this “Agreement”) is entered into this 15th day of August, 2006 (the “Effective Date”), by and between Ceragenix Corporation (“Ceragenix”), a Colorado corporation, and Osmotics Corporation (“Osmotics”), a Colorado corporation (each a “Party,” and collectively, the “Parties”).
Patent Sublicense AgreementPatent Sublicense Agreement • November 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • November 16th, 2022
GIAR ENERGY S.R.L. SOCIETA’ BENEFIT, a company under Italian law, with registered office in San Severino Marche (MC - Italy) at Borgo Conce n. 29 – Company Registration Number of Marche Region, Fiscal Code and VAT No. 02064820430 – in the person of its legal representative, Mr. Simone D’Ambrosio,
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • August 1st, 2016 • Limelight Networks, Inc. • Services-business services, nec • Massachusetts
The parties in the lawsuit styled: Akamai Technologies, Inc. and Massachusetts Institute of Technology vs. Limelight Networks, Inc., Civil Action No. 06-cv-11109RWZ (the “Lawsuit”) hereby agree to settle all claims and controversies in the Lawsuit as of August 1, 2016 (the “Effective Date”), according to the following terms:
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDPatent Sublicense Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the “Agreement”) by and between mRNA RiboTherapeutics, Inc., a Wisconsin company (“mRNA RiboTherapeutics”) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (“Company”). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). mRNA RiboTherapeutics and Company may herein each be referred to as a "Party" or collectively as the "Parties".
SECOND AMENDMENT TO PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • March 25th, 2009 • Ceragenix Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus
This agreement is entered into this day of March 2009 by and between Osmotics Corporation (“Osmotics”) and Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (collectively the “Parties”).
WILUS CELLULAR PORTFOLIO – PATENT SUBLICENSE AGREEMENT BETWEEN SISVEL AND [LICENSEE SHORT NAME]Patent Sublicense Agreement • April 10th, 2024
This Patent Sublicense Agreement (“Agreement”), effective as of [Effective date] (“Effective Date”), is entered into by and between Sisvel International S.A., a company having its principal place of business at Immeuble Cubus C2, 2, rue Peternelchen, L-2370 Howald, Grand Duchy of Luxembourg (“Sisvel” or “Licensor”) and [Licensee complete name], a company duly incorporated under the laws of [Licensee Incorporation State], having its registered office at [Licensee address] ("[Licensee short name]" or “Licensee”) (individually, a “Party” and collectively, the “Parties”).
ContractPatent Sublicense Agreement • May 10th, 2012 • A123 Systems, Inc. • Miscellaneous electrical machinery, equipment & supplies
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
FIRST AMENDMENT TO THE EXCLUSIVE PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • January 13th, 2017 • MyDx, Inc. • Measuring & controlling devices, nec
THIS FIRST AMENDMENT TO THE EXCLUSIVE PATENT SUBLICENSE AGREMENT (this “Sublicense Amendment Agreement”) is made as of November 29, 2016 (the “Effective Date”) by and between CDx, Inc., a Delaware corporation with its principal place of business at 6335 Ferris Square, Suite B, San Diego, CA 92121 (“CDx”), and Next Dimension Technologies, Inc., a California corporation with its principal place of business at 1 West Mountain Street, #11, Pasadena, CA 91103 (“NDT”). CDx and NDT are sometimes referred to herein individually as the “Party” or collectively as the “Parties”.
DRUG DELIVERY PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New Jersey
This Drug Delivery Patent Sublicense Agreement (Agreement) is entered into as of May 2002 (Effective Date) by and between Amersham Health A.S. (formerly Nycomed Imaging A.S.), a company organized under the laws of Norway with offices at Nycoveien 2, Post Office Box 4220, Torshov, N-0401, Oslo, Norway (AH), and KS Avicenna, Inc. (formerly INTELLIgene Expressions Inc.) a corporation organized under the laws of Canada, with offices at Edmonton Research Park, 1938-94 Street, Edmonton, Alberta, Canada T6N 1J3 (KSA).
ContractPatent Sublicense Agreement • March 12th, 2012 • A123 Systems, Inc. • Miscellaneous electrical machinery, equipment & supplies
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDPatent Sublicense Agreement • March 30th, 2021 • BioNTech SE • Biological products, (no disgnostic substances)
This is the Second Amendment ("Second Amendment") to the Patent Sublicense Agreement which became effective on July 19, 2017, as amended in the First Amendment which became effective on February 10, 2020 (together, the “Agreement”) by and between CELLSCRIPT, LLC, a Wisconsin company (“Cellscript”) and BioNTech RNA Pharmaceuticals GmbH, a German corporation (“Company”). This Second Amendment is effective as of August 1, 2020 ("Second Amendment Effective Date"). Cellscript and Company may herein each be referred to as a "Party" or collectively as the "Parties".
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • February 4th, 2011 • Avax Technologies Inc • Biological products, (no disgnostic substances) • Illinois
This Patent Sublicense Agreement (“Sublicense Agreement”) is entered into and made as of April 27, 2009 (“Effective Date”) between AVAX Technologies, Inc. (“AVAX”), a New York corporation having a place of business at 2000 Hamilton Street, Suite 204, Philadelphia, Pennsylvania 19130, and Cancer Treatment Centers of America, Inc. (“CTCA”), an Illinois corporation having a place of business at 1336 Basswood Road, Schaumburg, Illinois 60173.
AMENDMENT TO PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • July 13th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments
THIS AMEDMENT TO PATENT SUBLICENSE AGREEMENT (this “Amendment”) is made this 28th day of June, 2018 (the “Amendment Effective Date”) between:
SECTION 1 DEFINITIONSPatent Sublicense Agreement • March 28th, 1997 • Cardiovascular Diagnostics Inc /Nc/ • Electromedical & electrotherapeutic apparatus
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • March 11th, 2004 • Cymer Inc • Special industry machinery, nec • Massachusetts
THIS PATENT SUBLICENSE AGREEMENT (“Sublicense Agreement”), made as of this 7 day of Nov., 2003 (the “Effective Date”), by and between SCIENCE RESEARCH LABORATORY, INC., a Massachusetts corporation with principal offices at 15 Ward Street, Somerville, Massachusetts 02143 (“SRL”) and CYMER, INC., a Nevada corporation, with principal offices at 17075 Thornmint Court, San Diego California 92127 (“Cymer”).
Exhibit 10.11 ------------- PATENT SUBLICENSE AGREEMENT --------------------------- THIS PATENT SUBLICENSE AGREEMENT (the "Agreement") is entered into as of the Effective Time by and between Hyundai Electronics Industries Co., Ltd., Hyundai Jeonja...Patent Sublicense Agreement • February 3rd, 2000 • Chippac LTD • Semiconductors & related devices • Illinois
SISVEL VP9 PATENT SUBLICENSE AGREEMENT BETWEEN SISVEL AND [ ]Patent Sublicense Agreement • February 18th, 2024
by and between Sisvel International S.A., a company having its principal place of business at Immeuble Cubus C2, 2, rue Peternelchen, L-2370 Howald, Grand Duchy of Luxembourg ;S͞isvel͟ Žƌ
SISVEL 5G MULTIMODE PROGRAM – PATENT SUBLICENSE AGREEMENT BETWEEN SISVEL AND [ ]Patent Sublicense Agreement • April 8th, 2024
This sublicense agreement (“Agreement”), effective as of January 1, 2024 (“Effective Date”), is entered into by and between Sisvel International S.A., a company having its principal place of business at Immeuble Cubus C2, 2, rue Peternelchen, L-2370 Howald, Grand Duchy of Luxembourg (“Sisvel” or “Licensor”) and [ ], a company duly incorporated under the laws of Carrie Counterparty, having its registered office at 71 Stevenson St., San Francisco, California 94105, USA ("[ ]" or “Licensee”) (individually, a “Party” and collectively, the “Parties”).
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • November 16th, 2022
GIAR ENERGY S.R.L. SOCIETA’ BENEFIT, a company under Italian law, with registered office in San Severino Marche (MC - Italy) at Borgo Conce n. 29 – Company Registration Number of Marche Region, Fiscal Code and VAT No. 02064820430 – in the person of its legal representative, Mr. Simone D’Ambrosio,
Second Amended and Restated Non-Exclusive Patent Sublicense AgreementPatent Sublicense Agreement • August 12th, 2011 • Evergreen Energy Inc • Bituminous coal & lignite surface mining • Colorado
This Second Amended and Restated Non-Exclusive Patent Sublicense Agreement (“Agreement”), effective as of the “Effective Date,” is between C-LOCK Technology, Inc., a Delaware corporation having an address of 1225 - 17th Street, Suite 1300, Denver, CO 80202 (“CLT”), Evergreen Energy Inc., a Delaware corporation having an address of 1225 - 17th Street, Suite 1300, Denver, CO 80202 (“Evergreen” ) and C-LOCK Inc. (“CLI”), a South Dakota corporation, with its principal place of business at 233 Westberry Court North, Rapid City, SD 57702.
PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • November 13th, 2007 • MiddleBrook Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This PATENT SUBLICENSE AGREEMENT (this “Agreement”) is made as of ___, 200___between Kef Pharmaceuticals, Inc., a Delaware corporation (“Kef”), and MiddleBrook Pharmaceuticals, Inc., a Delaware corporation (“MiddleBrook”). Kef and MiddleBrook are each referred to individually as a “Party,” and collectively as the “Parties.”
